LB Pharmaceuticals (LBRX) announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, CCO. Before joining LB Pharmaceuticals, Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics (NMRA)
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals Reports Strong Q3 and Strategic Progress
- LB Pharmaceuticals reports Q3 EPS (61c) vs ($39.49) last year
- LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs
- Opening Day: Cerebras Systems withdraws IPO filing
- Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential